Single Domain Antibody Development Service

Single domain antibody (SdAb) is an antibody fragment that contains only a single antibody variable region and is the smallest antibody unit ever obtained that can stably bind antigen. Alfa Cytology has extensive experience in antibody therapy, and aims to provide one-stop development services for single domain antibody for biotech and biopharmaceutical companies worldwide.

Introduction to Single Domain Antibody

Single domain antibody (SdAb), originally referring to a class of antibodies found in camels and sharks, has emerged as a promising alternative to traditional therapeutic antibody (mAb). SdAb is exceptionally stable fragments derived from the antigen-binding domains of immunoglobulins.

Fig. 1 Schematic diagram of antibody evolution. (Wang, M., et al. 2024)

The current cancer burden of prostate cancer is gradually increasing and new diagnostic and therapeutic approaches need to be explored. And single domain antibodies, which have the advantages of small size, high stability, easy processing and modification, are increasingly used in the diagnosis and therapy of prostate cancer.

Advantages of Single Domain Antibody

Single domain antibodies offer a number of advantages over monoclonal antibodies (mAbs), and they have great potential to improve drug efficacy and safety.

Single domain antibody can be stabilized under extreme conditions such as high temperature, high pressure, low pH, and low protease concentration.

Enhanced Stability

Single domain antibody has a high degree of modification and engineering flexibility to incorporate additionalfunctionality and targets multiple pathways simultaneously.

Highly Flexible

Single domain antibody exhibits reduced immunogenicity, minimizing the likelihood of immune responses and improving patient tolerance during therapy.

Less Immunogenic

Our Services

Alfa Cytology deeply understands and foresees that single domain antibody therapies will be the key to treating prostate cancer in the future. Our company continues to build and improve its core technology platform, focusing on the research and development of innovative single-domain antibody therapeutics to ensure the efficiency and feasibility of research and development.

• SdAb-drug Conjugates

Single domain antibodies are designed to couple to cytotoxic drugs or other therapeutic molecules, thereby improving drug targeting and reducing damage to normal cells.

• Bispecific and Multispecific SdAbs

Focuses on the development of single-domain antibodies capable of recognizing multiple targets simultaneously, enhancing the immune system's attack on cancer cells, or blocking multiple cancer-related signaling pathways simultaneously.

• Cell Therapy Based SdAbs

Use of single-domain antibodies for cellular therapeutic strategies, such as expression of specific single-domain antibodies by genetically engineered modified T-cells (CAR-T cells) for enhanced recognition and killing of prostate cancer cells.

Workflow of Single Domain Antibody Development

Alfa Cytology aims to provide customized one-stop development services to support your innovations and breakthroughs in the field of prostate cancer therapy in order to accelerate the development and commercialization of new therapies. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.